Karyopharm Therapeutics
Michael Kauffman serves as Chairman of the Board at FoRx Therapeutics and Chairperson of the Board at Incendia Therapeutics and BiVictriX Therapeutics plc. As CEO and President of Nereid Therapeutics, Michael Kauffman leads innovative efforts in drug development. Co-founder of Karyopharm Therapeutics Inc., Michael Kauffman has played a significant role in the discovery and commercialization of XPOVIO® (NEXPOVIO®) for multiple myeloma and lymphoma. Additionally, Michael Kauffman has held various advisory positions and board memberships, including Lead Director at Verastem Oncology and Board Member at Kezar Life Sciences. Michael Kauffman earned an MD and PhD in Molecular Biology and Biochemistry from The Johns Hopkins University School of Medicine and attended Amherst College.
This person is not in any teams
This person is not in any offices
Karyopharm Therapeutics
13 followers
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).